Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Aker BioMarine ASA ( (DE:1PG) ).
Aker BioMarine reported a strong start to 2025 with a 5% year-over-year increase in Q1 revenue, reaching USD 50.8 million, and a significant 59% rise in adjusted EBITDA. The Human Health Ingredients segment was a key driver of growth, with a 16% increase in revenue, supported by demand in China, Europe, and South America. The Consumer Health Products segment also saw a 4% revenue increase, aligning with broader market trends. The company is focusing on operational improvements and cost efficiency to navigate macroeconomic uncertainties and new tariffs, while maintaining a leaner cost base.
More about Aker BioMarine ASA
Aker BioMarine is a leading innovator in human health and nutrition, specializing in krill-derived products for consumer health and nutrition. The company offers a range of products including Superba Krill Oil, Lysoveta, FloraMarine, and PL+, along with the consumer brand Kori Krill. Aker BioMarine is uniquely positioned in the industry, sourcing krill from the pristine waters of Antarctica. The company is also involved in sustainability initiatives through its spin-offs AION and Understory, and is listed on the Oslo Stock Exchange.
YTD Price Performance: -25.36%
Technical Sentiment Signal: Sell
Current Market Cap: €370.9M
For detailed information about 1PG stock, go to TipRanks’ Stock Analysis page.